Is the LION strong enough?

References

• 1 Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J. Clin. 66(1), 7–30 (2016).Crossref, Medline, Google Scholar
• 2 du Bois A, Quinn M, Thigpen T et al. 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Ann. Oncol. 16(Suppl. 8), viii7–viii12 (2005).Crossref, Medline, Google Scholar
• 3 Panici PB, Maggioni A, Hacker N et al. Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial. J. Natl Cancer Inst. 97(8), 560–566 (2005).Crossref, Medline, Google Scholar
• 4 Morice P, Joulie F, Rey A et al. Are nodal metastases in ovarian cancer chemoresistant lesions? Analysis of nodal involvement in 105 patients treated with preoperative chemotherapy. Eur. J. Gynaecol. Oncol. 25(2), 169–174 (2004).Medline, CAS, Google Scholar
• 5 Chan JK, Urban R, Hu JM et al. The potential therapeutic role of lymph node resection in epithelial ovarian cancer: a study of 13, 918 patients. Br. J. Cancer 96(12), 1817–1822 (2007).Crossref, Medline, CAS, Google Scholar
• 6 du Bois A, Reuss A, Harter P et al. Potential role of lymphadenectomy in advanced ovarian cancer: a combined exploratory analysis of three prospectively randomized Phase III multicenter trials. J. Clin. Oncol. 28(10), 1733–1739 (2010).Crossref, Medline, Google Scholar
• 7 Gao J, Yang X, Zhang Y. Systematic lymphadenectomy in the treatment of epithelial ovarian cancer: a meta-analysis of multiple epidemiology studies. Jpn J. Clin. Oncol. 45(1), 49–60 (2015).Crossref, Medline, Google Scholar
• 8 Harter P, Sehouli J, Lorusso D et al. LION: Lymphadenectomy in ovarian neoplasms – a prospective randomized AGO study group led gynecologic cancer intergroup trial. J. Clin. Oncol. 35(15 Suppl.), 5500–5500 (2017).Crossref, Google Scholar
• 9 Zhou J, Sun J-Y, Wu S-G et al. Risk factors for lymph node metastasis in ovarian cancer: implications for systematic lymphadenectomy. Int. J. Surg. Lond. Engl. 29, 123–127 (2016).Crossref, Medline, Google Scholar
• 10 Takeshima N, Hirai Y, Umayahara K, Fujiwara K, Takizawa K, Hasumi K. Lymph node metastasis in ovarian cancer: difference between serous and non-serous primary tumors. Gynecol. Oncol. 99(2), 427–431 (2005).Crossref, Medline, Google Scholar
• 11 Ataseven B, Grimm C, Harter P et al. Prognostic value of lymph node ratio in patients with advanced epithelial ovarian cancer. Gynecol. Oncol. 135(3), 435–440 (2014).Crossref, Medline, Google Scholar
• 12 Tangjitgamol S, Manusirivithaya S, Sheanakul C et al. Can we rely on the size of the lymph node in determining nodal metastasis in ovarian carcinoma? Int. J. Gynecol. Cancer 13(3), 297–302 (2003).Crossref, Medline, CAS, Google Scholar
• 13 Pereira A, Magrina JF, Rey V, Cortes M, Magtibay PM. Pelvic and aortic lymph node metastasis in epithelial ovarian cancer. Gynecol. Oncol. 105(3), 604–608 (2007).Crossref, Medline, Google Scholar
• 14 Eisenkop SM, Spirtos NM. The clinical significance of occult macroscopically positive retroperitoneal nodes in patients with epithelial ovarian cancer. Gynecol. Oncol. 82(1), 143–149 (2001).Crossref, Medline, CAS, Google Scholar
• 15 Keyver-Paik M-D, Arden JM, Lüders C et al. Impact of chemotherapy on retroperitoneal lymph nodes in ovarian cancer. Anticancer Res. 36(4), 1815–1824 (2016).Medline, Google Scholar